Uncategorized
Aerpio Announces Presentations on Novel Treatments for Glaucoma and Retinal Diseases at ARVO 2018 Annual Meeting
CINCINNATI--(BUSINESS WIRE)--Aerpio Pharmaceuticals, Inc. (OTCQB:ARPO), a biopharmaceutical company focused on advancing first-in-class treatments for ocular diseases, presented new preclinical and clinical results for several of its development programs at the Association for Research in Vision and Ophthalmology (ARVO) 2018 annual meeting in Honolulu, HI this week. The three presentations are listed below: Subcutaneous Administration of AKB-9778, a Tie2 Activator, Reduces IOP in Patients with